How to Verify SS-31 (Elamipretide) Purity and Batch Documentation
A laboratory-focused guide to verifying SS-31 (Elamipretide) identity, purity and batch documentation, with the analytical methods and study context researchers use to assess research-grade peptide material.
SS-31, also written as elamipretide and known in the literature as a mitochondria-targeted tetrapeptide, is a synthetic aromatic-cationic peptide whose sequence is L-arginyl-L-lysyl-L-phenylalanyl-L-alanine (commonly abbreviated D-Arg-Dmt-Lys-Phe-NH2 in the D-arginine/2',6'-dimethyltyrosine analog nomenclature used in the mitochondrial-targeting literature). It is classified as a cell-penetrating, mitochondria-targeted peptide; the evidence block supplied for this page does not state a CAS number, molecular formula or molecular weight, so those identifiers should be confirmed against the certificate of analysis accompanying each lot rather than assumed. The work described here centres on the mitochondrial inner membrane and the electron transport chain, with the peptide studied for its interaction with cardiolipin-rich membrane environments and for effects on oxidative phosphorylation, reactive oxygen species handling and mitochondrial-dependent apoptotic signalling.
Verification of research-grade SS-31 therefore rests on three separable questions: is the material the correct molecule, is it sufficiently pure for the intended assay, and does the batch documentation let a reviewer reconstruct how those two claims were established. The sections below summarise the study context in which the compound has been characterised, because the analytical thresholds a laboratory sets should follow the sensitivity of the model it intends to run.
Research Studies
SS-31 and mitochondrial function in aged female mice with MASLD
A comparative study in aged female C57BL/6 mice (12–14 months) fed a high-fat, high-fructose diet for 16 weeks to induce metabolic dysfunction-associated steatotic liver disease randomised animals into control diet, MASLD, MASLD plus MitoQ, and MASLD plus SS-31 arms, with MitoQ dosed at 25 mg/kg/day [1]. The study framed early mitochondrial dysfunction as a driver of lipid imbalance, inflammation and fibrosis in MASLD, and compared the two mitochondria-targeted agents across mitochondrial function, oxidative stress, apoptosis and inflammation endpoints [1]. This is an animal model; the findings describe aged female mice under nutritional stress and do not establish human outcomes.
SS-31 and radiation-induced cardiomyocyte senescence
In cardiomyoblast H9C2 cells and human induced pluripotent stem cell-derived cardiomyocytes, exposure to gamma-radiation at 2, 5 and 10 Gy inhibited H9C2 proliferation in a dose-dependent manner and induced senescence-associated beta-galactosidase staining [3]. The study evaluated whether the mitochondrial-targeted peptide SS-31 (elamipretide) attenuates radiation-induced cell senescence in these cell systems, noting that no strategies were available to prevent the phenomenon at the time of the work [3]. These are in vitro findings in cardiomyoblast and hiPSC-derived cardiomyocyte cultures.
SS-31 and alpha-synuclein membrane binding and aggregation
SS-31 was examined for its capacity to modulate the interaction of alpha-synuclein with lipid membranes and to mitigate mitochondrial impairment induced by alpha-synuclein oligomers, a line of work motivated by the association between alpha-synuclein membrane binding and aggregation and Parkinson's disease and related synucleinopathies [4]. Using fluorescence correlation spectroscopy and fluorescence anisotropy, the study demonstrated that SS-31 displaces both wild-type and N-terminally acetylated alpha-synuclein from membranes [4]. The peptide is described in that work as a therapeutic tetrapeptide with alternating cationic and aromatic residues and known mitochondrial inner membrane binding and oxidative stress-reducing properties [4]. This is a biophysical and cell-based study.
SS-31 and Barth syndrome: clinical trial documentation
A Phase 3b/4 randomised, double-blind, parallel-group, placebo-controlled trial is evaluating the efficacy, safety and pharmacokinetics of once-daily subcutaneous elamipretide in subjects with genetically confirmed Barth syndrome over 72 weeks [5]. The stated primary objective is to confirm efficacy of elamipretide, which is approved in the United States under the name FORZINITY under accelerated approval based on improvement in knee extensor muscle strength as an intermediate clinical endpoint [5]. This is a registered human trial record; it is included here as documentation context, not as an efficacy claim for research material.
SS-31 and healthy aging with physical function endpoints
A separate registered study plans a daily elamipretide dose for 4 weeks, screening sufficient subjects to enrol 30 participants, with baseline measurement, a 4-week intervention period, a midpoint check-in phone interview at 2 weeks plus or minus 3 days, post-intervention visits mirroring baseline, and a 2-week follow-up after the last injection concluding with an end-of-study contact [7]. This is a registered protocol record describing study design and schedule.
SS-31 and expanded access documentation
An intermediate-size expanded access protocol for elamipretide states that the treating physician must contact the sponsor using the provided expanded access contacts, and that elamipretide is made available only after careful review of an individual request submitted by the treating physician [8]. Under that protocol, initiation and conduct of treatment for an individual patient, and compliance with the treatment guideline, fall under the full and sole responsibility of the treating physician [8]. This is a regulatory and access document.
SS-31 and gestational diabetes mellitus: mitochondrial and redox context
Mitochondrial dysfunction and redox imbalance are increasingly recognised as factors in the pathophysiology of gestational diabetes mellitus, where impaired oxidative phosphorylation in the placenta, increased reactive oxygen species production and insufficient antioxidant protection impair bioenergetics and affect maternal-foetal nutrient exchange [6]. The same literature describes alterations in mitochondrial dynamics and mitophagy as additional risk factors for placental disease, and characterises the placenta as more than a passive recipient of maternal hyperglycaemia [6]. This review-level material provides context for why mitochondria-targeted tool compounds are studied; it does not report SS-31 administration.
SS-31 and mitochondrial dysfunction in arthritic and neurotrauma models
Related work reports that mitochondrial dysfunction and abnormal activation of the cGAS-STING signalling pathway play a key role in rheumatoid arthritis, a condition described as remaining a therapeutic challenge because of its complex pathological microenvironment and poorly elucidated etiology [9]. Separately, time-resolved proteomics applied to mouse brains after controlled cortical impact with seawater immersion was used to examine whether seawater immersion amplifies pathology or reshapes the temporal trajectory of post-traumatic biology, identifying mitochondrial oxidative stress as a modifiable target [10]. These reports support the broader rationale for mitochondria-directed research reagents; they are not studies of SS-31 itself.
What batch documentation should let you reconstruct
Because the evidence block does not supply a sequence, formula or molecular weight for SS-31, the practical verification route is documentary. A usable lot record should allow an independent reviewer to answer the questions in the table below without contacting the supplier.
| Verification question | What the record should show | Why it matters for assay design |
|---|---|---|
| Identity | Confirmatory mass spectrometry consistent with the stated peptide, plus the supplier's stated sequence and any synonyms used on the label | Mitochondria-targeted peptides are studied at concentrations where a wrong-sequence impurity can dominate a membrane-binding readout |
| Purity | Chromatographic purity with the method and detection wavelength stated, and the integration method identified | Senescence, apoptosis and oxidative-stress endpoints are sensitive to trace contaminants |
| Counter-ion and salt form | Stated salt or counter-ion, since this changes the mass of material weighed per mole of peptide | Dosing calculations in mg/kg in animal work depend on the actual peptide content |
| Lot traceability | Lot number linking the vial to the certificate, with a retest or expiry date | Longitudinal studies such as a 16-week dietary model require a single characterised lot [1] |
| Storage and handling | Recommended storage conditions and any documented stability data | Peptide integrity at the time of use, not at the time of manufacture, is what the experiment depends on |
Where a supplier cannot supply a confirmatory identity method, the material is not suitable for work in which the peptide itself is the variable under test. Where the intended model is a cell system, such as the H9C2 and hiPSC-derived cardiomyocyte cultures used in the radiation senescence work [3], or a biophysical membrane assay of the kind used in the alpha-synuclein studies [4], the purity threshold should be set against the sensitivity of that specific readout rather than a generic figure.
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing, administration or medical guidance of any kind. Nothing on this page is a recommendation to use SS-31 or any other compound in a person. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress — https://europepmc.org/article/PMC/PMC13580669
- [2] Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress — https://europepmc.org/article/PMC/PMC13580669
- [3] Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence — https://europepmc.org/article/PMC/PMC13400571
- [4] Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of alpha-Synuclein and Restores Impaired Mitochondrial Function — https://pubmed.ncbi.nlm.nih.gov/42219795/
- [5] Clinical Trial in Patients With Barth Syndrome — 4TAZPower — https://clinicaltrials.gov/study/NCT07531251
- [6] Redox imbalance and mitochondrial dysfunction in gestational diabetes mellitus — https://pubmed.ncbi.nlm.nih.gov/42242082/
- [7] Study of Healthy Aging and Physical Function With Elamipretide — https://clinicaltrials.gov/study/NCT07275424
- [8] An Intermediate Size Expanded Access Protocol of Elamipretide — https://clinicaltrials.gov/study/NCT04689360
- [9] Engineered Mitochondria-Targeted Biomimetic Hybrid Nanovesicles Ameliorate Rheumatoid Arthritis via Regulating Macrophage Autophagy and cGAS-STING Signaling — https://pubmed.ncbi.nlm.nih.gov/42709510/
- [10] Seawater immersion reshapes the temporal dynamics of traumatic brain injury and reveals mitochondrial oxidative stress as a modifiable therapeutic target — https://pubmed.ncbi.nlm.nih.gov/42600764/